“Therapeutically equivalent” means substitutable, according to the FDA’s lexicon. However, the fact that Amphastar and the FDA are still in labeling discussions (according to Amphastar) makes it less than crystal clear what the outcome will be. Time for NVS/MNTA to file a lawsuit.